The World Health Organization (WHO) has authorized the emergency use of the Janssen vaccine - the pharmaceutical arm of Johnson & Johnson - against Covid-19. The release came just over a week after the Brazilian government announced the purchase of 38 million doses of the immunizer. The units, however, should only be delivered in the second half of this year.
This means that the Johnson & Johnson vaccine can now be offered by Covax, the coalition led by the WHO to guarantee immunizations against Covid-19 on an equal basis to all countries. "As new vaccines become available, we must ensure that they are part of the global solution and not another reason why some countries and people are left behind," says Tedros Adhanom, director-general of WHO.
In Brazil, the National Health Surveillance Agency (Anvisa) released the use of vaccines that arrive through Covax. Thus, there is no need for a new registration or emergency authorization by the agency.
The Janssen vaccine is especially interesting, as it requires only one application to protect against the new coronavirus - unlike CoronaVac and Covishield, which are used in Brazil, but whose protection is subject to two doses. In addition, the immunizer is easier to store and can be kept in regular refrigerators.
Johnson & Johnson recently entered into agreements with competing pharmaceutical companies to increase the production capacity of its vaccines. Sanofi Pasteur, for example, says it can manufacture around 12 million units of the immunizer - it just needed to be authorized by the European Medicines Agency (EMA).
Um study the US Food and Drug Administration (FDA) proved that Johnson & Johnson's formula is 76,7% effective against severe cases after 14 days of application and 85,4% after 28 days. In relation to moderate to severe cases, the efficacy is 66,9% and 66,1% after 14 and 28 days, respectively.
The survey had the participation of more than 40 thousand volunteers from eight countries, including Brazil, USA and South Africa.